RecruitingPhase 3NCT05451004
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer. A Phase III Randomized Controlled Trial
Sponsor
Canadian Cancer Trials Group
Enrollment
510 participants
Start Date
Feb 10, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single Photon Emission Computed Tomography (SPECT-CT), compared to the usual treatment when radiotherapy is given to both sides of the neck?
Eligibility
Min Age: 18 Years
Inclusion Criteria18
- Patients with pathologically proven diagnosis of lateralized OPC (tonsil, tongue base, soft palate, or pharyngeal wall) not involving or crossing midline.
- HPV positive or negative (by p16 immunohistochemistry).
- Clinical stage T1-3 M0 (UICC/AJCC TNM 8th Edition). Nodal involvement may include no nodes or single or multiple ipsilateral lymph nodes (largest ≤6cm in maximum diameter)
- Radiological investigations within 8 weeks of registration:
- CT or MRI of the neck (with head imaging as indicated);
- PET-CT scan
- Chest CT scan
- Planned definitive RT or CRT with bilateral neck RT (patients planned for unilateral neck RT are excluded).
- Intent to deliver concurrent chemotherapy or not must be known at the time of randomization. As this is a pragmatic trial, even patients who are not candidates for systemic therapy will be eligible for participation.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
- Willing to complete the quality of life and/or health utility questionnaire, if sufficiently fluent in available language(s).
- Informed consent prior to registration
- Accessible for treatment and follow-up.
- Commencement of definitive RT within 28 days (+ 14 days) of randomization.
- Injection procedure for lymphatic mapping may be performed in the nuclear medicine, ambulatory clinic, or operating room setting
- Women/men of childbearing potential must have agreed to use a highly effective contraceptive method
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
- Patient must consent to provision of, and investigator(s) must confirm location and commitment to obtain a representation of formalin fixed paraffin block of non-cytology tumour tissue in order that the specific correlative marker assays
Exclusion Criteria11
- T1-T2 cancers isolated to the tonsil fossa (i.e. without any soft palate, tongue base, posterior pharyngeal wall or posterior tonsil pillar involvement) with no involved lymph nodes or with a single ipsilateral node \< 3 cm without extranodal extension.
- Tonsil or tongue base primary cancer who have previously undergone diagnostic palatine or lingual tonsillectomy with either complete excision or with no clinically apparent residual disease
- Previous head and neck cancer or multiple synchronous primary head and neck cancers
- Previous induction or neo-adjuvant chemotherapy.
- Previous radiation therapy to the head and neck or comprehensive neck dissection of at least 3 levels on either side (due to potential for disrupted lymphatic channels and drainage pathways). Patients who have had excisional biopsies of involved lymph nodes are eligible
- Radiotracer allergy
- Severe, active co-morbidity including any of the following:
- Chronic Obstructive Pulmonary Disease or other pulmonary illness requiring hospitalization within 30 days of registration
- Unstable angina and/or congestive heart failure requiring hospitalization within the 30 days of registration
- Acute myocardial infarction within 30 days of study registration
- Diseases precluding RT (e.g. scleroderma)
Interventions
OTHERLymphatic Mapping with SPECT-CT
Radiation: Ipsilateral Neck Radiotherapy and SPECT-CT Guided Contralateral Neck Radiotherapy
RADIATIONIpsilateral and Contralateral Neck
Radiotherapy
Locations(33)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05451004
Related Trials
Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
NCT072091891 location
A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer
NCT054915127 locations
Role of Liquid Biopsies in HPV-associated Cancer Treatment Monitoring
NCT057745611 location
Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC)
NCT063056762 locations
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer
NCT072906211 location